STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer (STELLA-2)
Primary Purpose
Endometrial Neoplasms, Ovarian Neoplasms
Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Extraperitoneal Laparoscopic aortic lymphadenectomy
Transperitoneal Laparoscopic aortic lymphadenectomy
Sponsored by
About this trial
This is an interventional treatment trial for Endometrial Neoplasms focused on measuring extraperitoneal, transperitoneal, laparoscopic aortic lymphadenectomy, endometrial cancer, ovarian cancer, surgical staging
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of endometrial cancer confirmed by histopathological analysis (endometrial biopsy) requiring surgical staging according to FIGO (the International Federation of Gynecology and Obstetrics) recommendations
- Diagnosis of ovarian cancer confirmed by histopathological analysis after an initial cystectomy or oophorectomy without suspicion of neoplasia thus requiring additional surgical staging according to FIGO recommendations
Exclusion Criteria:
- Diagnosis of advanced endometrial cancer based on findings on imaging techniques (CT, MRI and/or PET)
- Diagnosis of advanced endometrial or ovarian cancer based on intraoperative findings (e.g. peritoneal carcinomatosis at initial laparoscopy)
- Patients who underwent previous aortic lymphadenectomy
- Patients who received previous pelvic and/or aortic radiotherapy
Sites / Locations
- Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Extraperitoneal
Transperitoneal
Arm Description
Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
Outcomes
Primary Outcome Measures
Surgical complications
Composite outcome defined by including at least one of the following:
Total estimated blood loss > 500 mL during surgery
Blood transfusion
Intraoperative complication classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Early postoperative complication (within 30 days after surgery) classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Late postoperative complication (past 30 days after surgery) classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Conversion to laparotomy during the aortic lymphadenectomy
Inability to complete the aortic lymphadenectomy
Secondary Outcome Measures
Number of lymph nodes
The number of lymph nodes (absolute number) is specified by the pathologist on histopathological analysis of the sample sent by the surgeon after surgical staging is realized (laparoscopic aortic lymphadenectomy). This variable is subdivided into: supra-mesenteric and infra-mesenteric.
Operative time
Total duration of surgery (from initial skin incision to end of skin suture), and total aortic lymphadenectomy time (time spent since the beginning of aortic lymphadenectomy to its completion). Metric: minutes.
Hospital stay
The number of days that patients stay in the hospital after surgery, measured in days from the day of the surgery to the day the patient is discharged from the hospital.
Overall survival
Number of patients alive after surgery.
Disease-free survival
Period of time in which there is no appearance of the symptoms or effects of the disease.
Full Information
NCT ID
NCT02676726
First Posted
October 14, 2015
Last Updated
October 23, 2019
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Collaborators
European Regional Development Fund
1. Study Identification
Unique Protocol Identification Number
NCT02676726
Brief Title
STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer
Acronym
STELLA-2
Official Title
STELLA 2 Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes, Evaluating Complications
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
September 2019 (Actual)
Study Completion Date
September 8, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Collaborators
European Regional Development Fund
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether or not there are more complications in the extraperitoneal compared with the transperitoneal approach for laparoscopic aortic lymphadenectomy for the surgical staging of endometrial or ovarian cancer
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Neoplasms, Ovarian Neoplasms
Keywords
extraperitoneal, transperitoneal, laparoscopic aortic lymphadenectomy, endometrial cancer, ovarian cancer, surgical staging
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
208 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Extraperitoneal
Arm Type
Experimental
Arm Description
Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
Arm Title
Transperitoneal
Arm Type
Active Comparator
Arm Description
Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
Intervention Type
Procedure
Intervention Name(s)
Extraperitoneal Laparoscopic aortic lymphadenectomy
Other Intervention Name(s)
Extraperitoneal laparoscopic para-aortic lymphadenectomy, Retroperitoneal laparoscopic lumbo-aortic lymphadenectomy
Intervention Description
Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Intervention Type
Procedure
Intervention Name(s)
Transperitoneal Laparoscopic aortic lymphadenectomy
Other Intervention Name(s)
Transperitoneal laparoscopic para-aortic lymphadenectomy, Transperitoneal laparoscopic lumbo-aortic lymphadenectomy
Intervention Description
Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Primary Outcome Measure Information:
Title
Surgical complications
Description
Composite outcome defined by including at least one of the following:
Total estimated blood loss > 500 mL during surgery
Blood transfusion
Intraoperative complication classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Early postoperative complication (within 30 days after surgery) classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Late postoperative complication (past 30 days after surgery) classified as Dindo grade III or worse, related to the aortic lymphadenectomy
Conversion to laparotomy during the aortic lymphadenectomy
Inability to complete the aortic lymphadenectomy
Time Frame
intraoperatively, within 30 days after surgery, and past 30 days after surgery up to 3 months after surgery
Secondary Outcome Measure Information:
Title
Number of lymph nodes
Description
The number of lymph nodes (absolute number) is specified by the pathologist on histopathological analysis of the sample sent by the surgeon after surgical staging is realized (laparoscopic aortic lymphadenectomy). This variable is subdivided into: supra-mesenteric and infra-mesenteric.
Time Frame
Postoperatively (within 1 week), at the moment of histopathologic examination
Title
Operative time
Description
Total duration of surgery (from initial skin incision to end of skin suture), and total aortic lymphadenectomy time (time spent since the beginning of aortic lymphadenectomy to its completion). Metric: minutes.
Time Frame
At the time of the surgery
Title
Hospital stay
Description
The number of days that patients stay in the hospital after surgery, measured in days from the day of the surgery to the day the patient is discharged from the hospital.
Time Frame
Measured the day the patient is discharged (up to 100 days)
Title
Overall survival
Description
Number of patients alive after surgery.
Time Frame
up to 3 years after surgery
Title
Disease-free survival
Description
Period of time in which there is no appearance of the symptoms or effects of the disease.
Time Frame
up to 3 years after surgery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of endometrial cancer confirmed by histopathological analysis (endometrial biopsy) requiring surgical staging according to FIGO (the International Federation of Gynecology and Obstetrics) recommendations
Diagnosis of ovarian cancer confirmed by histopathological analysis after an initial cystectomy or oophorectomy without suspicion of neoplasia thus requiring additional surgical staging according to FIGO recommendations
Exclusion Criteria:
Diagnosis of advanced endometrial cancer based on findings on imaging techniques (CT, MRI and/or PET)
Diagnosis of advanced endometrial or ovarian cancer based on intraoperative findings (e.g. peritoneal carcinomatosis at initial laparoscopy)
Patients who underwent previous aortic lymphadenectomy
Patients who received previous pelvic and/or aortic radiotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonio Gil Moreno, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Berta Diaz Feijoo, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Alejandro Correa Paris, MD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
M. Assumpció Pérez-Benavente, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Silvia Franco Camps, MD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jose Luis Sánchez Iglesias, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Silvia Cabrera Díaz, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Oriol Puig Puig, MD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Javier De La Torre, MD, PhD
Organizational Affiliation
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
12. IPD Sharing Statement
Citations:
PubMed Identifier
8641608
Citation
Vasilev SA, McGonigle KF. Extraperitoneal laparoscopic para-aortic lymph node dissection. Gynecol Oncol. 1996 Jun;61(3):315-20. doi: 10.1006/gyno.1996.0149.
Results Reference
background
PubMed Identifier
18835020
Citation
Dowdy SC, Aletti G, Cliby WA, Podratz KC, Mariani A. Extra-peritoneal laparoscopic para-aortic lymphadenectomy--a prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol. 2008 Dec;111(3):418-24. doi: 10.1016/j.ygyno.2008.08.021. Epub 2008 Oct 2.
Results Reference
background
PubMed Identifier
18365538
Citation
Gil-Moreno A, Maffuz A, Diaz-Feijoo B, Puig O, Martinez-Palones JM, Perez A, Garcia A, Xercavins J. Modified approach for extraperitoneal laparoscopic staging for locally advanced cervical cancer. J Exp Clin Cancer Res. 2007 Dec;26(4):451-8.
Results Reference
background
PubMed Identifier
16431320
Citation
Gil-Moreno A, Diaz-Feijoo B, Morchon S, Xercavins J. Analysis of survival after laparoscopic-assisted vaginal hysterectomy compared with the conventional abdominal approach for early-stage endometrial carcinoma: a review of the literature. J Minim Invasive Gynecol. 2006 Jan-Feb;13(1):26-35. doi: 10.1016/j.jmig.2005.08.013.
Results Reference
background
PubMed Identifier
18538379
Citation
Gil-Moreno A, Diaz-Feijoo B, Perez-Benavente A, del Campo JM, Xercavins J, Martinez-Palones JM. Impact of extraperitoneal lymphadenectomy on treatment and survival in patients with locally advanced cervical cancer. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S33-5. doi: 10.1016/j.ygyno.2008.03.024. Epub 2008 Jun 5.
Results Reference
background
PubMed Identifier
18607826
Citation
Gil-Moreno A, Franco-Camps S, Diaz-Feijoo B, Perez-Benavente A, Martinez-Palones JM, Del Campo JM, Parera M, Verges R, Castellvi J, Xercavins J. Usefulness of extraperitoneal laparoscopic paraaortic lymphadenectomy for lymph node recurrence in gynecologic malignancy. Acta Obstet Gynecol Scand. 2008;87(7):723-30. doi: 10.1080/00016340802136343.
Results Reference
background
PubMed Identifier
24361579
Citation
Pakish J, Soliman PT, Frumovitz M, Westin SN, Schmeler KM, Reis RD, Munsell MF, Ramirez PT. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol. 2014 Feb;132(2):366-71. doi: 10.1016/j.ygyno.2013.12.019. Epub 2013 Dec 20.
Results Reference
background
PubMed Identifier
20188409
Citation
Dowdy SC, Mariani A. Lymphadenectomy in endometrial cancer: when, not if. Lancet. 2010 Apr 3;375(9721):1138-40. doi: 10.1016/S0140-6736(09)62068-7. Epub 2010 Feb 24. No abstract available.
Results Reference
background
PubMed Identifier
18304622
Citation
Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, Podratz KC. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008 Apr;109(1):11-8. doi: 10.1016/j.ygyno.2008.01.023. Epub 2008 Mar 4.
Results Reference
background
PubMed Identifier
20839058
Citation
Gil-Moreno A, Franco-Camps S, Cabrera S, Perez-Benavente A, Martinez-Gomez X, Garcia A, Xercavins J. Pretherapeutic extraperitoneal laparoscopic staging of bulky or locally advanced cervical cancer. Ann Surg Oncol. 2011 Feb;18(2):482-9. doi: 10.1245/s10434-010-1320-9. Epub 2010 Sep 14.
Results Reference
background
PubMed Identifier
24231134
Citation
Diaz-Feijoo B, Gil-Ibanez B, Perez-Benavente A, Martinez-Gomez X, Colas E, Sanchez-Iglesias JL, Cabrera-Diaz S, Puig-Puig O, Magrina JF, Gil-Moreno A. Comparison of robotic-assisted vs conventional laparoscopy for extraperitoneal paraaortic lymphadenectomy. Gynecol Oncol. 2014 Jan;132(1):98-101. doi: 10.1016/j.ygyno.2013.11.004. Epub 2013 Nov 11.
Results Reference
background
PubMed Identifier
34022445
Citation
Bebia V, Gil-Moreno A, Hernandez A, Gilabert-Estelles J, Franco-Camps S, de la Torre J, Siegrist J, Chipirliu A, Cabrera S, Bradbury M, Perez-Benavente A, Diaz-Feijoo B. Robot-assisted Extraperitoneal Para-aortic Lymphadenectomy Is Associated with Fewer Surgical Complications: A Post Hoc Analysis of the STELLA-2 Randomized Trial. J Minim Invasive Gynecol. 2021 Dec;28(12):2004-2012.e1. doi: 10.1016/j.jmig.2021.05.009. Epub 2021 May 20.
Results Reference
derived
PubMed Identifier
33160695
Citation
Diaz-Feijoo B, Bebia V, Hernandez A, Gilabert-Estalles J, Franco-Camps S, de la Torre J, Segrist J, Chipirliu A, Cabrera S, Perez-Benavente A, Gil-Moreno A. Surgical complications comparing extraperitoneal vs transperitoneal laparoscopic aortic staging in early stage ovarian and endometrial cancer. Gynecol Oncol. 2021 Jan;160(1):83-90. doi: 10.1016/j.ygyno.2020.10.038. Epub 2020 Nov 5.
Results Reference
derived
Learn more about this trial
STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer
We'll reach out to this number within 24 hrs